{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:34:05Z","timestamp":1775187245926,"version":"3.50.1"},"reference-count":52,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002853","type":"journal-article","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:38:44Z","timestamp":1069385924000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Propentofylline for dementia"],"prefix":"10.1002","author":[{"given":"Maria A","family":"Frampton","sequence":"first","affiliation":[{"name":"4 Edwin Terrace Mellifont Avenue Dun Laoire Co. Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Harvey","sequence":"additional","affiliation":[{"name":"University of Melbourne; Aged Psychiatric Services; The Geelong Hospital PO BOX 281 Geelong Victoria Australia 3220"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Kirchner","sequence":"additional","affiliation":[{"name":"MHCOP, Whittington Hospital; A13 Charterhouse Building, Archway Campus London UK N19 5NF"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,4,22]]},"reference":[{"key":"10.1002\/14651858.CD002853-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1749-6632.2000.tb06410.x","article-title":"Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. parallel study populations in two randomized, placebo-controlled trials","volume":"903","author":"Kittner","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD002853-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Kittner B European\/Canadian Propentofylline Study Group Using a combined randomized start\/withdrawal design to assess propentofylline's effect on disease progression in Alzheimer's disease and vascular dementia Journal of Neural Transmission 2000b 15","DOI":"10.1016\/S0924-977X(99)80437-4"},{"key":"10.1002\/14651858.CD002853-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Kittner B European\/Canadian Propentofylline Study Group Using a combined randomized start\/withdrawal design to assess propentofylline's effects on disease progression in Alzheimer's disease and vascular dementia: results of clinical studies Journal of the European College of Neuropsychopharmacology 1999e S320","DOI":"10.1016\/S0924-977X(99)80437-4"},{"key":"10.1002\/14651858.CD002853-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Kittner B Wilmot C Assessing propentofylline's impact on progression of alzheimer's disease and vascular dementia using a novel combind withdrawal\/delayed onset design Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver 1999d 131","DOI":"10.1016\/S0924-977X(99)80437-4"},{"key":"10.1002\/14651858.CD002853-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Rother M European\/Canadian Propentofylline Study Group A 72-week study assessing propentofylline's safety, efficacy, and impact on disease progression in patients with alzheimer's disease The Gerontologist 1999d 8","DOI":"10.1016\/S0924-977X(99)80434-9"},{"key":"10.1002\/14651858.CD002853-BIB0006|cit6","unstructured":"Rother M European\/Canadian Propentofylline Study Group A 72-week study assessing the effects of propentofylline in patients with Alzheimer's disease: Safety, efficacy, and impact on disease progression Journal of Neural Transmission 2000 16"},{"key":"10.1002\/14651858.CD002853-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Rother M European\/Canadian Propentofylline Study Group A 72-week, placebo-controlled study assessing propentofylline's safety, efficacy, and impact on disease progression in patients with Alzheimer's disease Journal of the European College of Neuropsychopharmacology 1999b S319","DOI":"10.1016\/S0924-977X(99)80434-9"},{"key":"10.1002\/14651858.CD002853-BIB0008|cit8","unstructured":"Rother M European\/Candian Propentofylline Study Group Long-term effects of propentofylline in patients with alzheimer's disease: safety, efficacy, and impact on disease progession Journal of the American Geriatrics Society 1999a S2"},{"key":"10.1002\/14651858.CD002853-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Rother M Kittner B Propentofylline for the treatment of Alzheimer's disease a double blind placebo controlled trial assessing safety effiacy and impact on disease progression Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver 1999c 74","DOI":"10.1016\/S0924-977X(99)80434-9"},{"key":"10.1002\/14651858.CD002853-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1749-6632.2000.tb06410.x","article-title":"Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. parallel study populations in two randomozed, placebo-controlled trials","volume":"903","author":"Kittner","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1002\/14651858.CD002853-BIB0011|cit11","first-page":"15","article-title":"Using a combined randomized start\/withdrawal design to assess propentofylline's effect on disease progression in Alzheimer's disease and vascular dementia","volume":"107","author":"Kittner","year":"2000b","journal-title":"Journal of Neural Transmission"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002853-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.1016\/S0924-977X(99)80437-4","article-title":"Using a combined randomized start\/withdrawal design to assess propentofylline's effects on disease progression in Alzheimer's disease and vascular dementia: results of clinical studies","volume":"9","author":"Kittner","year":"1999e","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD002853-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Kittner B Wilmot C Assessing propentofylline's impact on progression of alzheimer's disease and vascular dementia using a novel combind withdrawal\/delayed onset design Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver 1999d 131","DOI":"10.1016\/S0924-977X(99)80437-4"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002853-BIB0014|cit14","first-page":"S166","volume":"13","author":"Kittner","year":"1999","journal-title":"Alzheimer's Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD002853-BIB0015|cit15","unstructured":"Schweiger C Erkinjuntti T European\/Canadian Propentofylline Study Group Propentofylline for the treatment of vascular dementia: A double blind placebo controlled trial assessing safety, efficacy, and impact on disease progression Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver 1999c 74"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002853-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/S0924-977X(99)80435-0","article-title":"A 48-week, placebo-controlled study examining propentofylline's safety, efficacy, and impact on disease progression in patients with vascular dementia","volume":"9","author":"Schweiger","year":"1999a","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD002853-BIB0017|cit17","first-page":"16","article-title":"Propentofylline for the treatment of vascular dementia: A 48-week study assessing safety, efficacy, and impact on disease progression","volume":"107","author":"Schweiger","year":"2000","journal-title":"Journal of Neural Transmission"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002853-BIB0018|cit18","first-page":"143","article-title":"A 48-week study assessing propentofylline's safety, efficacy, and impact on disease progression in patients with vascular dementia","volume":"39","author":"Schweiger","year":"1999b","journal-title":"The Gerontologist"},{"issue":"2","key":"10.1002\/14651858.CD002853-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00002093-200004000-00008","article-title":"Propentofylline treatment for Alzheimer's disease and vascular dementia: an economic evaluation based on functional abilities","volume":"14","author":"Bachynsky","year":"2000","journal-title":"Alzheimer's Disease and Associated Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002853-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000051188","article-title":"Propentofylline in the treatment of Alzheimer's disease and Vascular dementia: a review of phase III trials","volume":"9","author":"Rother","year":"1998","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD002853-BIB0021|cit21","first-page":"361","article-title":"Propentofylline(HWA 285): A subgroup analysis of phase III clinical trials in Alzheimer's disease and vascular dementia","volume-title":"Alzheimer's disease: From molecular biology to therapy","author":"Kittner","year":"1996"},{"key":"10.1002\/14651858.CD002853-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000106650","article-title":"A 12-month, randomised, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R","volume":"8","author":"Marcusson","year":"1997","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD002853-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0022-510X(96)00127-X","article-title":"Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia","volume":"141","author":"Mielke","year":"1996","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD002853-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-510X(97)00217-7","article-title":"Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease","volume":"154","author":"Mielke","year":"1998","journal-title":"Journal of Neurological Sciences"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD002853-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/S0197-4580(96)80615-4","article-title":"Propentofylline enhances brain activation during memory stimulation in Alzheimer's disease-a PET study with 18-FDG","volume":"17","author":"Mielke","year":"1996b","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD002853-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2007-1014297","article-title":"Placebo-controlled trial of the xanthine derivative propentofylline in dementia","volume":"27","author":"M\u00f6ller","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD002853-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000119482","article-title":"Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies","volume":"24","author":"Saletu","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD002853-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1749-6632.1997.tb48481.x","article-title":"Clinical trials in dementia with propentofylline","volume":"826","author":"Kittner","year":"1997","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD002853-BIB0029|cit29","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"issue":"2","key":"10.1002\/14651858.CD002853-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00002093-200004000-00008","article-title":"Propentofylline treatment for Alzheimer's disease and vascular dementia: an economic evaluation based on functional abilities","volume":"14","author":"Bachynsky","year":"2000","journal-title":"Alzheimer's Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD002853-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/glia.440070117","article-title":"Cytotoxicity of microglia","volume":"7","author":"Banati","year":"1993","journal-title":"Glia"},{"key":"10.1002\/14651858.CD002853-BIB0032|cit32","first-page":"36","article-title":"Can the pathophysiology of dementia lead to rational therapy?","volume-title":"Treatment Development Strategies for Alzheimer's Disease","author":"Bowen","year":"1986"},{"key":"10.1002\/14651858.CD002853-BIB0033|cit33","article-title":"Cochrane Reviewers\u2019 Handbook 4.0 [updated July 1999]","volume-title":"RevMan [computer programme] version 4","author":"Clarke","year":"1999"},{"key":"10.1002\/14651858.CD002853-BIB0034|cit34","unstructured":"Erzigkeit H Syndrome Short Test SKT: Ein Kurztest zur Erfassung von Gedachtnis- und Aufmerksamkeitsstorungen 1986"},{"key":"10.1002\/14651858.CD002853-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-Mental-State\" - a practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD002853-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Archives of Gerontology and Geriatrics"},{"key":"10.1002\/14651858.CD002853-BIB0037|cit37","first-page":"217","article-title":"CGI-Clinical Global Impression","volume-title":"ECDEU Assessment for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD002853-BIB0038|cit38","unstructured":"Kessler J Schaaf A Mielke R Hogrefe Verlag fur Psychologie 1993"},{"key":"10.1002\/14651858.CD002853-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1749-6632.1997.tb48481.x","article-title":"Clinical trials in dementia with propentofylline","volume":"826","author":"Kittner","year":"1997","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002853-BIB0040|cit40","first-page":"S166","article-title":"Clinical trials of propentofylline in vascular dementia","volume":"13","author":"Kittner","year":"1999","journal-title":"Alzheimer's Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD002853-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1749-6632.2000.tb06410.x","article-title":"Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. parallel study populations in two randomozed, placebo-controlled trials","volume":"903","author":"Kittner","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD002853-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical Diagnosis of Alzheimer\u2019s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002853-BIB0043|cit43","first-page":"341","volume":"12","author":"Oswald","year":"1979","journal-title":"Z Gerontol"},{"key":"10.1002\/14651858.CD002853-BIB0044|cit44","unstructured":"Hoechst Press release 1998"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002853-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000051188","article-title":"Propentofylline in the treatment of Alzheimer's disease and Vascular dementia: a review of phase III trials","volume":"9","author":"Rother","year":"1998","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD002853-BIB0046|cit46","unstructured":"Schaaf A Kessler J Grond M Fink G 1992"},{"key":"10.1002\/14651858.CD002853-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD002853-BIB0048|cit48","first-page":"226","article-title":"The Prevalence of Neuropathologically confirmed vascular dementia: Findings from the Nun Study","volume":"4","author":"Snowdon","year":"1999","journal-title":"Alzheimer's Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD002853-BIB0049|cit49","first-page":"221","volume-title":"A Compendium of Neuropsychological Tests","author":"Spreen","year":"1991"},{"key":"10.1002\/14651858.CD002853-BIB0050|cit50","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research","author":"World Health Organisation","year":"1993"},{"key":"10.1002\/14651858.CD002853-BIB0051|cit51","first-page":"915","volume":"20","author":"Zerssen","year":"1970","journal-title":"Arzneimittel-forschung"},{"issue":"2","key":"10.1002\/14651858.CD002853-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002853","article-title":"Propentofylline for dementia","author":"Frampton","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002853\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:13:15Z","timestamp":1628543595000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002853"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2003,4,22]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002853","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,22]]}}}